Lucentis Receives Priority Review
The BLA for Genentech's wet age-related macular degeneration therapy Lucentis (ranibizumab) has been granted six-month priority review by FDA. The user fee date has been set for June 29, 2006
The BLA for Genentech's wet age-related macular degeneration therapy Lucentis (ranibizumab) has been granted six-month priority review by FDA. The user fee date has been set for June 29, 2006